Slide 1: Insulet Corporation Q1 2024 Earnings
Insulet Corporation Q1 2024 Earnings May 9, 2024
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials and the approval of products by regulatory bodies. These forward-looking statemen
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company uses the following non-GAAP financial measures: • Constant currency revenue growth, which represents the change in revenue between current and prior year periods using the exchange rate in effect during the applicable prior year period. Insulet presents consta
Slide 4: Financial Highlights
Financial Highlights 1 Revenue Performance - Q1'24 • Total Company - $441.7 million, an increase of 23.3%, or 22.8% in constant currency • Total Omnipod - $433.0 million, an increase of 21.1%, or 20.5% in constant currency • U.S. Omnipod - $317.7 million, an increase of 22.7% • International Omnipod
Slide 5: Recent Strategic Highlights
Recent Strategic Highlights Expand Access & Awareness International Innovation & Clinical • Launched U.S. limited market release (LMR) of • >50% of new customer starts in Q1 were Omnipod 5 • On track for U.S. full market release (FMR) of Omnipod 5 integrated with Dexcom's G7 Omnipod 5 with G7 and LM
Slide 6: Financial Performance
Financial Performance 1 1 Total Revenue & Growth Rates U.S. Omnipod Revenue and Growth Rates 30% 41% 23% $1,697M $1,251M 20% 36% 22% $1,305M 24% $1,099M $885M 25% $904M 23% $652M 23% $527M 49% 23% $358M $442M $318M $259M 2020 2021 2022 2023 Q1'23 Q1'24 2020 2021 2022 2023 Q1'23 Q1'24 2 1 Adjusted Gr
Slide 7: Key Commercial Metrics – Q1 2024
~85% >50% of U.S. New Customer Starts of International NCS were (NCS) were MDI Omnipod 5 Key ~25% Significant Increase Commercial of U.S. NCS were Type 2 in International NCS due to Omnipod 5 Metrics – Q1 2024 Vast Majority Sensor of Choice of U.S. Volume in First Two European through Pharmacy Marke
Slide 8: Product Development Status - Q1 2024
Product Development Status - Q1 2024 Legend U.S. Commercial Product Regulatory Innovation Pipeline International Strategy Development Classic Omnipod Omnipod DASH U.S. FMR August 2022 Omnipod 5 U.K. FMR in June 2023 CE Mark September 2022 w/ G6 Germany FMR in August 2023 Netherlands LMR in April 202
Slide 9: Guidance Highlights - 2024
Guidance Highlights - 2024 1 Revenue Guidance Raise 1,2 Margin Guidance Raise 1 Assumptions & Drivers Q2'24 FY'24 FY'24 Gross FY'24 Operating Revenue Revenue Margin Margin • Continued strong Omnipod 5 adoption globally 15% to 18% 14% to 18% 68% to 69% ~13.5% Closer to mid-point • Expect NCS and reve
Slide 10: Revenue Guidance Reconciliation
Revenue Guidance Reconciliation FY 2024 Q2 2024 Revenue Growth Currency Revenue Growth Currency GAAP Impact Constant Currency GAAP Impact Constant Currency U.S. Omnipod 17% to 21% —% 17% to 21% 21% to 24% —% 21% to 24% International Omnipod 11% to 14% (1)% 12% to 15% 10% to 13% (2)% 12% to 15% Total
Slide 11: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures % of % of % of % of % of % of FY 2023 Revenue FY 2022 Revenue FY 2021 Revenue FY 2020 Revenue Q1'2024 Revenue Q1'2023 Revenue Total Revenue GAAP Growth Rate 30.0% 18.8% 21.5% 22.5% 23.3% 21.2% Less: Currency Impact 0.4% (3.7)% 1.8% 0.6% 0.5% (2.1)% Constant Curren